Rare and Orphan Disease Trials

Using AI to Identify Rare Disease Trial Candidates

Posted on digi By digi

Recruiting patients for rare disease clinical trials is notoriously difficult due to low prevalence, heterogeneous clinical presentations, and long diagnostic odysseys. Traditional recruitment methods often fail because they rely on small physician networks or manual chart reviews. Patients with rare disorders frequently face diagnostic delays averaging 5–7 years, which severely limits the pool of eligible participants when new therapies become available. As a result, trials often experience delays, under-enrollment, or termination, undermining the development of treatments that could dramatically impact patient outcomes.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials

Regulatory Risk Assessment for Rare Disease Clinical Development

Posted on digi By digi

Rare disease clinical development faces unique regulatory uncertainties due to small patient populations, limited data, and high unmet medical needs. A proactive regulatory risk assessment is essential to identify, prioritize, and mitigate compliance, ethical, and operational risks that may affect approval timelines and trial integrity.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Decentralized Data Capture in Global Rare Disease Trials

Posted on digi By digi

Global rare disease trials face significant logistical and operational challenges. With patients often scattered across different countries and continents, traditional on-site data collection models result in delays, cost overruns, and participant burden. Decentralized data capture offers a patient-centric solution by enabling remote and real-time collection of trial data, significantly improving efficiency and trial inclusivity.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials

Implementing Risk-Based Monitoring in Rare Disease Trials

Posted on digi By digi

Risk-Based Monitoring (RBM) has become a cornerstone of modern clinical trial management, replacing traditional 100% on-site Source Data Verification (SDV) with a more strategic, data-driven approach. For rare disease studies—where patient populations are small, trial budgets are constrained, and geographic dispersion is common—RBM offers a particularly valuable set of tools.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Integrating Wearable Devices in Rare Disease Clinical Trials

Posted on digi By digi

Rare disease clinical trials face challenges such as small populations, geographically dispersed patients, and the need for long-term monitoring. Wearable devices—ranging from wristbands and accelerometers to advanced biosensors—are increasingly being adopted to overcome these barriers. They offer continuous, real-world data collection on patient activity, vital signs, and disease-specific endpoints, reducing the burden of frequent site visits.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials

Using Genomic Databases for Rare Disease Trial Recruitment

Posted on digi By digi

Rare disease trials face a unique bottleneck—finding eligible participants within very small patient populations. Many rare diseases are defined by genetic mutations, and access to genomic databases enables sponsors and investigators to identify suitable patients more effectively. These databases, often developed from population-wide sequencing initiatives, biobanks, or disease-specific registries, provide detailed variant data linked to clinical phenotypes.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials

Navigating Compassionate Use Programs from a Regulatory Perspective

Posted on digi By digi

For patients with rare and life-threatening diseases, access to investigational therapies before formal marketing authorization can be life-saving. Compassionate Use—also known as Expanded Access—provides a regulated pathway for patients who are not eligible for clinical trials to receive promising treatments still under investigation.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Mining Electronic Health Records for Rare Disease Patient Identification

Posted on digi By digi

Identifying eligible patients for rare disease clinical trials is one of the greatest barriers in orphan drug development. Unlike common diseases with large patient databases, rare disease patients are often scattered across different health systems, misdiagnosed, or not tracked consistently. Electronic Health Records (EHRs) provide a powerful solution by aggregating longitudinal patient data across healthcare providers, enabling more efficient identification of trial candidates.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials

Virtual Reality Tools for Rare Disease Patient Education

Posted on digi By digi

Effective patient education is central to clinical trial success, particularly in rare disease studies where participants and caregivers often lack prior exposure to research environments. Informed consent documents are typically lengthy and full of technical language, which may overwhelm families already facing the stress of managing a rare condition. Virtual reality (VR) tools present a unique opportunity to transform patient education by providing immersive, interactive, and easily understandable experiences.
Click to read the full article.

Data & Technology, Rare and Orphan Disease Trials